Last reviewed · How we verify
Doxazosin extended release
Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.
Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Hypertension.
At a glance
| Generic name | Doxazosin extended release |
|---|---|
| Also known as | Cardozin XL 4mg Prolonged-release Tablets, Cardura XL, Cardura |
| Sponsor | University of Arkansas |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Urology |
| Phase | FDA-approved |
Mechanism of action
Doxazosin blocks alpha-1 adrenergic receptors on smooth muscle cells in the prostate, bladder neck, and blood vessels. This causes vasodilation and smooth muscle relaxation, reducing urinary obstruction symptoms in benign prostatic hyperplasia and lowering systemic vascular resistance to reduce blood pressure in hypertension. The extended-release formulation provides sustained drug delivery for once-daily dosing.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Headache
- Hypotension
- Syncope
- Rhinitis
Key clinical trials
- A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
- Doxazosin for Psychostimulant Dependence (PHASE1, PHASE2)
- Black Education and Treatment of Hypertension (BEAT HTN) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxazosin extended release CI brief — competitive landscape report
- Doxazosin extended release updates RSS · CI watch RSS
- University of Arkansas portfolio CI